Enhancing patient-centred approaches to optimise early-breast cancer care: A review of current practice and opportunities for improvement in Singapore
Enhancing patient-centred approaches to optimise early-breast cancer care: A review of current practice and opportunities for improvement in Singapore
“Enhancing patient-centred approaches to optimise early-breast cancer care: a review of current practice and opportunities for improvement in Singapore” is a research report by Economist Impact sponsored by MSD, which examines the existing breast cancer care pathway in Singapore and the factors that help or hinder the goal of achieving optimal patient-centred care.
Related content
Enhancing patient-centred approaches to optimise early-breast cancer care:...
Breast cancer is the most common cancer and the leading cause of cancer death among women in South Korea. Both the number of newly diagnosed patients and the age-standardised rate of breast cancer are increasing every year, with 28,049 newly diagnosed breast cancer patients in 2018, an increase of 6.1% from 2017. It is estimated that there were an additional 28,032 women diagnosed in 2022.
Breast cancer diagnosed at an early stage, when it is not too large and has not spread, is more likely to be treated successfully than breast cancer diagnosed at an advanced stage. In South Korea, the proportion of patients with Stage 0 and Stage I breast cancer has steadily increased since 2002 and accounts for more than half of the total breast cancer cases since 2010. Advanced breast cancer not only creates an urgent health challenge but also impedes the quality of life, and brings significant economic costs for patients, their families and public health systems.
There are significant opportunities to improve breast cancer care in South Korea by understanding the patient-centred care pathway for early breast cancer diagnosis and treatment and investigating the unmet needs in managing breast cancer.
Using an evidence-based approach that incorporates a review of existing data and an expert panel meeting, we designed a force field analysis to assess existing policies and system performance across four domains of the patient journey: population awareness, screening and diagnosis, treatment, and survivorship.
Indicators within each domain were selected based on evidence of their impact on promoting or deterring optimisation of patient-centred care for early breast cancer. We then shared the findings with South Korean stakeholders to gain local perspectives. We drafted scores for indicators within these four domains based on our research and these local insights. This report combines in-depth research and force field analysis of early breast cancer care in South Korea.
Key findings:• Population awareness: Population awareness is crucial for early detection of breast cancer, to encourage screening and better health-seeking behaviour. Patient advocacy groups in South Korea play a big role toward promoting breast cancer awareness, and there are initiatives in place to educate the public, spread knowledge, and encourage research in breast cancer.
However despite these efforts, the lack of knowledge of the risk factors associated with breast cancer including dense breasts is a challenge that must be tackled to optimise patient-centred early breast cancer care.
• Screening and Diagnosis: In South Korea, both organised and opportunistic breast cancer screening programmes exist through the National Cancer Screening Programme (NCSP), which recommends breast cancer screening through mammography every two years for women aged 40–69 years old. The screening rate has remained high at above 60% since 2010, and this has led to an increase in early diagnosis and a decrease in mortality rates. Barriers to screening exist however, including mistrust and concern over the efficacy of the NCSP, and fear of diagnosis. To overcome these barriers and enhance patientcentred care, the benefits and preventive nature of screening should be emphasised, and stigma should be addressed.
• Treatment: Inclusion of the patient voice in reimbursement decision making, low out of pocket costs for treatment, and an increased focus on shared decision-making between health care professionals and patients have been identified as enablers towards better patient-centred care. However the lack of a multidisciplinary team approach in treating breast cancer patients in local hospitals and adequate psychological support as well as difficulties in accessing new innovative medicines at the local level have been highlighted as barriers where improvements are needed.
• Survivorship: The number of survivors among patients with breast cancer in South Korea has been increasing steadily, and follow-up and survivorship care are important considerations for patients. In South Korea efforts are in place to address these long-term needs, however in practice survivors still report difficulties in accessing the information and help they need after completion of their treatment.
Throughout the patient journey for early breast cancer in South Korea, there are many positive steps in place which promote optimisation of patient-centred care, however there are also areas where improvements can be made, and it is here that focus should be given to reach the ultimate goal of better patient-centred early breast cancer care.
Video | Enhancing patient-centred approaches to optimise early-breast cance...
“Enhancing patient-centred approaches to optimise early-breast cancer care: a review of current practice and opportunities for improvement in New Zealand” is a research report by Economist Impact examining the existing breast cancer care pathway in New Zealand and the factors that help or hinder the goal of achieving optimal patient-centred care.
The research aims to understand the unmet needs within the health system and opportunities for improvement. We analyse how New Zealand can improve patient-centred care and build awareness, promote screening, early detection, diagnosis and prognosis, and ensure access to high-quality treatment, including supportive and palliative care.
Enhancing patient-centred approaches to optimise early-breast cancer care: A review of current practice in South Korea
Enhancing patient-centred approaches to optimise early-breast cancer care: A review of current practice in South Korea
Breast cancer is the most common cancer and the leading cause of cancer death among women in South Korea. Both the number of newly diagnosed patients and the age-standardised rate of breast cancer are increasing every year, with 28,049 newly diagnosed breast cancer patients in 2018, an increase of 6.1% from 2017. It is estimated that there were an additional 28,032 women diagnosed in 2022.
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.
The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Enhancing patient-centred approaches to optimise early-breast cancer care: A review of current practice and opportunities for improvement in Thailand
Enhancing patient-centred approaches to optimise early-breast cancer care: A review of current practice and opportunities for improvement in Thailand
Related content
Enhancing patient-centred approaches to optimise early-breast cancer care i...
New Zealand is amongst the countries with the highest prevalence of breast cancer, affecting one in nine women, and more than 600 deaths every year. The incidence rate exceeds the OECD average and is second only to Australia. According to the WHO New Zealand Cancer profile, the total breast cancer cases per year are expected to increase by 31% and reach 4,584 by 2040 from 3,504 in 2018.
Breast cancer diagnosed at an early stage, when it is not too large and has not spread, is more likely to be treated successfully than breast cancer diagnosed at an advanced stage. Advanced breast cancer not only creates an urgent health challenge but also impedes the quality of life, and brings significant economic costs for patients, their families and public health systems.
Low awareness, late diagnosis, and poor access to treatment especially for disadvantaged communities has meant that breast cancer outcomes can be poor. However, there are significant opportunities to improve breast cancer care in New Zealand by understanding the patient-centred care pathway for early breast cancer diagnosis and treatment and investigating the unmet needs in the management of breast cancer.
Using an evidence-based approach that incorporates a review of existing data and an expert panel meeting, we designed a force field analysis to assess existing policies and system performance across four domains of patient journey: population awareness, screening and diagnosis, treatment, and survivorship.
Indicators within each domain were selected based on evidence of their impact on promoting or deterring optimisation of patient-centred care for early breast cancer. We then conducted a workshop to discuss our findings and gain the perspective of key experts in New Zealand to flesh out key opportunities for improvement. Based on our research and insights from the workshop, we drafted scores for indicators within these four domains. This report combines indepth research and force field analysis of early breast cancer care in New Zealand.
Key findings:
Awareness: Awareness is the first step towards any change. It is critical to promote health literacy to increase participation in preventive care measures such as modifiable lifestyle changes and exercise, self-examination of breasts, regular check-ups with GPs, and screening for eligible candidates. Various stakeholders such as NGOs, patient advisory groups, the government etc., are involved in promoting awareness of early breast cancer and associated risk factors such as alcohol consumption and obesity. However, lack of access to information particularly for Māori and Pacific peoples is a big barrier to the optimisation of patient-centred care in New Zealand. Treatment: New Zealand last published guidelines for the management of early breast cancer in 2009.. These guidelines include informed decision-making and a multidisciplinary approach to treat cancer. However, there is a need to update the guidelines to deliver high quality, evidence based care, improve outcomes, reduce variation, and make good decisions with resources. New Zealand should consider how it equitably prioritises access to innovative medicines for its population. Survivorship: Continuity of care and psychological support for cancer survivors are important elements of patient centred care. In New Zealand, there is an opportunity for specialist nurses and primary care providers/GPs to offer continuous support to cancer survivors at the community level. Psychological support, though acknowledged, is identified as an unmet need, which must be addressed. Workforce: Workforce availability was identified as a cross cutting challenge across all steps of the patient journey. To optimise patient-centred care, there is a need to develop, retain, and up-skill the health workforce in New Zealand.We conclude with the following opportunities to optimise early breast cancer care and improve outcomes for people living with breast cancer in New Zealand:
1. Move beyond mortality and focus on quality of life: In New Zealand, the outcome measures for breast cancer management should go beyond simply mortality reduction. The target should be to improve quality of life by providing patientcentred care and support.2. Establish a coalition or alliance of stakeholders: To align the priorities of individuals impacted by breast cancer (patients and carers) and the preferences of the decision-makers, a breast cancer expert coalition or strategic alliance should be established with patient advocates, industry representatives, academia, and relevant healthcare professionals.3. Aspire for world-class care with improved access to innovative treatments: To meet the international standards of breast cancer care, the health system should identify the right outcomes and define tangible key performance indicators (KPIs) and quality performance indicators (QPIs). The aim should be to achieve improved patient-centred care and treatment options and ensure that health budgets are better targeted towards the interventions that would have the biggest effects on patient care and outcomes.4. Ensure screening programmes are available and are equitable: Since screening programmes play a vital role in early detection, impacting patient outcomes, monitoring and evaluating screening programmes at regular intervals is essential. The screening programme data, alongside important KPIs such as coverage and uptake, can be used to inform policy makers whether the screening programme is delivering the expected benefits or not. Ensuring timely uptake and availability of screening programmes is accessible for Māori and Pacific peoples is key to improving outcomes.
Video | Enhancing patient-centred approaches to optimise early-breast cance...
“Enhancing patient-centred approaches to optimise early-breast cancer care: a review of current practice and opportunities for improvement in New Zealand” is a research report by Economist Impact examining the existing breast cancer care pathway in New Zealand and the factors that help or hinder the goal of achieving optimal patient-centred care.
The research aims to understand the unmet needs within the health system and opportunities for improvement. We analyse how New Zealand can improve patient-centred care and build awareness, promote screening, early detection, diagnosis and prognosis, and ensure access to high-quality treatment, including supportive and palliative care.
Big plans, research and technology: highlights from the World Cancer Series: 2021
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high. The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Cancer control in the Czech Republic: Findings from the Index of Cancer Preparedness
Cancer control in the Czech Republic: Findings from the Index of Cancer Preparedness
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high. The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
World Lung Cancer Day
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high. The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Projet global de financement pour l’élimination du cancer du col de l’utérus : Financer la prévention secondaire dans les contextes de faible revenu
Projet global de financement pour l’élimination du cancer du col de l’utérus : Financer la prévention secondaire dans les contextes de faible revenu
Related content
Medidas globales de financiación para eliminar el cáncer de cuello uterino:...
El cáncer de cuello uterino es el cuarto cáncer que se detecta con mayor frecuencia en mujeres en todo el mundo, aunque es uno de los tipos de cáncer que mejor se pueden tratar y más se pueden prevenir si se detectan a tiempo. La morbilidad y la mortalidad del cáncer de cuello uterino afectan de forma dispar a las mujeres de países con unos ingresos bajos o entre bajos y medios, y aquellas de los países más pobres. En 2020, la Organización Mundial de la Salud (OMS) introdujo una iniciativa global para erradicar el cáncer de cuello uterino como problema de salud pública, y estableció objetivos intermedios para 2030.
Aunque existen dificultades en países con bajos recursos en torno a la viabilidad a largo plazo y la sostenibilidad económica de las iniciativas para abordar esta prioridad urgente de salud, la idea de conseguir una erradicación representa una nueva oportunidad de adoptar un enfoque de continuidad, en el que se toma como base la cobertura sanitaria universal y se exploran enfoques innovadores en cuanto a la financiación y la prestación a medida que los países amplían sus servicios de erradicación.
En este informe de The Economist Intelligence Unit se exploran algunos de desafíos de alto nivel asociados a la financiación de la erradicación del cáncer de cuello uterino en países con recursos limitados. Se aprovechar el conjunto de prioridades que se presenta a continuación para involucrar a los responsables de la toma de decisiones de financiación y políticas:
Generar información local para la toma de decisiones y el planteamiento de una financiación sanitaria. Se requiere un análisis en profundidad de la epidemiología, así como de los obstáculos para la detección del cáncer de cuello uterino y, cuando sea necesario, de los servicios de tratamiento de seguimiento en el ámbito del país, así como fundamentar la priorización de las soluciones más sostenibles y con el mayor impacto. Asimismo, dichos análisis deben identificar y abordar las deficiencias en materia de financiación y asignación de recursos dentro de los sistemas sanitarios.
Evaluar la financiación nacional y el alcance de los servicios de gran calidad mediante el uso de las herramientas disponibles de cálculo de costes y elaboración de modelos de la OMS para elaborar planes de ampliación graduales y viables. Las soluciones diseñadas para ajustarse a las limitaciones de asequibilidad y capacidad de cada país resultarán más sostenibles a largo plazo. Se debe dar prioridad al uso de las herramientas existentes de cálculo de costes y elaboración de modelos para identificar carencias y oportunidades para pasar gradualmente a programas de ámbito nacional. El éxito de los programas de erradicación depende de un enfoque sistemático y organizado, que se implementa a través del marco de una cobertura sanitaria universal bien planificada con presupuestos y planes de servicios sanitarios integrados.
Abogar por la integración en el ámbito de las políticas, la financiación, los programas y los servicios para alcanzar el éxito y la sostenibilidad. A la hora de abordar la sanidad pública, los enfoques independientes introducen deficiencias desde el punto de vista financiero que se deben evitar. Se debería obtener partido del solapamiento entre el cáncer de cuello uterino y otras prioridades de la sanidad pública —como el VIH y los servicios sanitarios de reproducción—, y aprovechar el marco de la estrategia de erradicación a nivel mundial de la OMS para generar una integración financiera. Se requiere un sólido liderazgo en el ámbitos nacional y de prestación de servicios para garantizar la integración y que se materialicen los beneficios asociados.
Utilizar soluciones financieras innovadoras y mixtas para complementar la financiación nacional. La financiación nacional de los servicios oncológicos —incluidos los del cáncer de cuello uterino— en países con bajos recursos es posible que no sea suficiente para ampliar los programas nacionales. Las consecuencias económicas globales de la pandemia de la COVID-19 afectarán aún más a los presupuestos sanitarios. Los países deben ampliar sus inversiones nacionales y hacer un mejor uso de los impuestos y los programas de seguros sociales, al tiempo que se aprovechan los sistemas de financiación suplementaria alternativos donde proceda. Debería plantearse un enfoque colaborativo por el que se aprovechen los bancos de desarrollo, la financiación mixta, el capital, la experiencia y la celeridad del sector privado.
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.Medidas globales de financiación para eliminar el cáncer de cuello uterino: financiación de servicios de prevención secundaria en países con bajos recursos
Medidas globales de financiación para eliminar el cáncer de cuello uterino: financiación de servicios de prevención secundaria en países con bajos recursos
El cáncer de cuello uterino es el cuarto cáncer que se detecta con mayor frecuencia en mujeres en todo el mundo, aunque es uno de los tipos de cáncer que mejor se pueden tratar y más se pueden prevenir si se detectan a tiempo. La morbilidad y la mortalidad del cáncer de cuello uterino afectan de forma dispar a las mujeres de países con unos ingresos bajos o entre bajos y medios, y aquellas de los países más pobres. En 2020, la Organización Mundial de la Salud
Related content
Projet global de financement pour l’élimination du cancer du col de l’utéru...
Le cancer du col de l’utérus est le quatrième cancer le plus courant chez les femmes à travers le monde. Pourtant, il s’agit de l’un des cancers les plus faciles à prévenir et à traiter en cas de détection précoce. Les femmes vivant dans les pays à revenu faible ou intermédiaire et les femmes les plus défavorisées au sein de tous les pays ont beaucoup plus de probabilités de développer un cancer du col de l’utérus et d’en mourir. En 2020, l’Organisation Mondiale de la Santé (OMS) a lancé une initiative mondiale visant à éliminer le cancer du col de l’utérus en tant que problème de santé publique, avec des objectifs intermédiaires à atteindre d’ici 2030.
Alors qu’il existe des défis dans les contextes de faible revenu au regard de la viabilité et la pérennité des financements des efforts liés à cette priorité de santé publique, l’ambition d’élimination représente une nouvelle opportunité d’adopter une approche globale. Il s’agira dès lors de s’appuyer sur la couverture de santé universelle et d’envisager des modes de financement et d’interventions innovants pour développer progressivement les services d’élimination de la maladie dans chaque pays.
Ce rapport de The Economist Intelligence Unit aborde les principaux défis liés au financement pour l’élimination du cancer du col de l’utérus dans des contextes de faible revenu. Les priorités listées ci-dessous peuvent servir à interpeller les dirigeants politiques ou les organismes de financement :
Recueillir des données locales pour mieux documenter la conception et les prises de décisions concernant les mécanismes de financement en santé. Dans chaque pays, il est indispensable de disposer d’une connaissance approfondie de l’épidémiologie et des freins qui pourraient s’opposer au déploiement du dépistage du cancer du col de l’utérus et, si nécessaire, à l’accès aux traitements, afin de donner la priorité aux solutions les plus efficaces et les plus durables. Ces analyses doivent aussi permettre d’identifier et de résoudre les problèmes de financement et de distribution des ressources au sein des systèmes de santé.
Déterminer les capacités de financement au niveau national dans chaque pays et la disponibilité de services de qualité à l’aide d’outils existants d’évaluation et de projection des coûts pour concevoir des programmes d’élimination adaptés et réalistes. À ce titre, des solutions adaptées aux possibilités et aux ressources de chaque pays seront plus pérennes. Les outils actuels d’évaluation et de projection des coûts doivent être utilisés en priorité pour identifier les opportunités et les insuffisances afin de pouvoir étendre progressivement les programmes d’élimination au niveau national. Leur bon fonctionnement repose sur une approche systématique et organisée, qui sera plus facile à déployer dans le cadre d’une couverture sanitaire universelle efficace, intégrant la budgétisation et la planification des services de santé.
Favoriser l’intégration de cet objectif aux enjeux politiques, au financement, à un programme et aux services de santé pour une efficacité durable. Les approches cloisonnées de la santé publique créent des inefficacités pouvant être minimisées ou complètement évitées. Les synergies avec d’autres priorités de santé publique, comme le VIH ou la planification familiale, doivent être recherchées. Le cadre de la stratégie mondiale de l’OMS pour l’élimination doit être utilisé pour promouvoir l’intégration financière. Un engagement fort des preneurs de décision aux niveaux mondial, national, programmatique et des services doit être encouragé pour s’assurer que l’intégration soit optimale et que tous les bénéfices en soient tirés.
Privilégier des solutions innovantes optimisant différentes sources de financement pour compléter le financement national.Dans des contextes de faible revenu, le financement national dédié aux services de lutte contre le cancer, dont le cancer du col de l’utérus, n’est pas suffisant pour développer des programmes à l’échelle nationale. Les conséquences financières mondiales de la pandémie de Covid-19 impacteront à long terme le financement de la santé. Les pays concernés doivent accroître leurs dépenses nationales de santé et améliorer leur utilisation des impôts et des systèmes d’assurance maladie, tout en favorisant l’utilisation d’autres systèmes de financement alternatifs lorsqu’ils sont disponibles. Des approches en consortium permettant de mobiliser des fonds auprès de banques de développement en combinant financement public et privé tout en favorisant l’expertise et la rapidité doit être envisagé.
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.Outside the hospital: cancer monitoring with apps
Patient monitoring apps allow patients with chronic diseases to report on their condition from outside of the hospital – where they spend most of their time – putting the patient, rather than the hospital, at the centre of the care pathway.
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high. The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
What can we do about the childhood cancers never diagnosed or treated?
What can we do about the childhood cancers never diagnosed or treated?
Over the next ten years we can look forward to seeing an additional 1m children surviving cancer around the world. This success story will be achieved through the concerted efforts of multiple agencies to support implementation of the World Health Organisation’s global initiative for childhood cancer. This was announced in 2018 and aims to increase survival rates to at least 60% by 2030.
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high. The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.